Stepstone Pharma

Stepstone Pharma is a specialty pharmaceutical company headquartered in Dublin, Ireland, dedicated to the development and commercialization of value-added medicines and orphan drugs. The company was founded by a group of experienced pharmaceutical executives with a track record of success at firms like Warner Chilcott and Elan. Stepstone Pharma focuses on identifying and acquiring late-stage clinical assets that offer significant therapeutic advantages in acute care and rare disease indications. Their most prominent project involved the ultra-short-acting beta-blocker Landiolol, for which they secured US rights and subsequently entered into a strategic licensing agreement with Eagle Pharmaceuticals. By leveraging their expertise in regulatory strategy and market access, Stepstone Pharma aims to bring innovative treatments to patients with high unmet medical needs.